The underling molecular mechanism of Ezrin activation in lung cancer involves Ezrin modifications (such as phosphorylation and S-nitrosylation), epidermal growth factor receptor (EGFR), and EGFR-mediated signaling pathways in non-small cell lung cancer (NSCLC) cells (Saygideger-Kont et al., 2016; Zhang et al., 2019). The gene discussed is EZR; the disease is lung cancer.